The clinical trial, sponsored by Jian-Kun Hu at West China Hospital, aims to evaluate the safety and efficacy of EpCAM-targeted CAR-T cell therapy for advanced gastric cancer with peritoneal metastasis. Given the high incidence of gastric cancer in China and the poor prognosis associated with peritoneal metastasis, this trial addresses a significant unmet medical need. If successful, the therapy could capture a substantial share of the gastric cancer treatment market, particularly in regions with high prevalence. The competitive landscape includes other CAR-T therapies and emerging immunotherapies, necessitating robust clinical data to establish differentiation. Diligence should focus on regulatory pathways, potential partnerships for commercialization, and the scalability of CAR-T cell manufacturing.